Julien Dodet
Amministratore Delegato presso Orano Med LLC
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Philippe Knoche | M | 55 |
Orano Med SAS
 Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.
Orano Cycle SA
 Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 13 anni |
| Jérôme Cordier | M | 58 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 12 anni |
| Loan Hoang-Sayag | M | 57 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
| Herve Riedinger | M | 66 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 5 anni |
| Valerie Alize | F | 60 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 7 anni |
| François Lurin | M | 55 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 7 anni |
| Anne Bihan Falanga | F | 71 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 7 anni |
| Jean-Luc Chastre | M | 66 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 7 anni |
| Nathalie Savel Hubert | F | 55 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 7 anni |
| Carine Cauffet Piquet | F | 51 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 7 anni |
| Cyril Moulin | M | 47 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 9 anni |
| Fabrice Chouraqui | M | - |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
| Vincent Martel | M | - |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | - |
| Eric Orsenna | M | - |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | - |
| Didier Benedetti | M | 71 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 22 anni |
| Martha Heitzmann-Crawford | M | 56 |
Orano Med LLC
 Orano Med LLC Medical SpecialtiesHealth Technology Orano Med LLC develops targeted cancer therapies using lead-212 (212Pb). The company is based in Bethesda, MD. The company is ultimately controlled by the Government of France. The CEO of the company is Julien Dodet. | - |
| Charles Hufnagel | M | - |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | - |
| Marc Quesnoy | M | - |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 21 anni |
| Dominique Delorme | M | - |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 24 anni |
| Agnès Russeil | F | - |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 18 anni |
| Guillaume Dureau | M | 62 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
| Olivier Wantz | M | 64 |
Orano Med LLC
Orano Med LLC Medical SpecialtiesHealth Technology Orano Med LLC develops targeted cancer therapies using lead-212 (212Pb). The company is based in Bethesda, MD. The company is ultimately controlled by the Government of France. The CEO of the company is Julien Dodet. | - |
| Frédéric Joël Desdouits | M | 57 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
| Thierry Laugel | M | 57 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
| Corinne Spilios | F | 54 |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Claire Vernet-Garnier | F | 40 |
Orano Cycle SA
Orano Cycle SA Other Metals/MineralsNon-Energy Minerals Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France. | 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Francia | 24 | 92.31% |
| Stati Uniti | 2 | 7.69% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Julien Dodet
- Contatti personali
